The 2026 American Diabetes Association guidance opens GLP-1 therapy to a new patient group.
A newly introduced federal bill would provide FDA-approved botanical drugs with 12 years of market exclusivity, a change that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results